INL Cluster

Pre-clinical evaluation of novel chemical compounds for cancer treatment: tackling unmet clinical needs

Despite all advances in the treatment of cancer, this is still one of the most frequent and deadliest diseases. Available therapies usually have limited efficacy and resistance mechanisms often occur. By integrating data from robust and well-structured in vitro and in vivo assays, CaTCh will investigate the antitumorigenic activity and biosafety of a panel of new chemical compounds in distinct tumor models. Agents were synthesized by the team and preliminary tests showed great anti-colorectal cancer activity (IC50 2-20x lower than IC50 of 5FU) in vitro. Of note, one particular compound (C10), while showing negligible toxicity in normal cell lines, was found to hit two key oncogenes for which no direct therapies are currently available. As the other drugs are family-derivatives of C10, a similar effect is foreseen, at least for some of them. CaTCh is expected to provide new, unique and most importantly efficacious solutions to cancer treatment thus tackling clinical unmet needs

Total Eligible Budget

239,879.80 €

INL Eligible Budget

36,875.00 €

Total Funding

239,879.80 €

INL Funding

36,875.00 €

Start Date


End Date


Type of action

SAICT – Projetos de investigação cientifica e desenvolvimento tecnológico (IC&DT)

Grant Agreement Id


Funding Agency


Funding Framework


INL Role


Approval Date


Intervention Region

North of Portugal